ስለ Dendreon Corporation
Dendreon Pharmaceuticals LLC is a biotechnology company. Its lead product, Provenge, is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.
Source: Wikipedia
ዋና መሥሪያ ቤትCorporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
የተመሠረተ2013
ሁኔታንቁ
ፓተንቶች134 ፓተንቶች
HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH…CA2923433C · 2020
Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with…US10261091B2 · 2019
ሁሉንም 134 ፓተንቶች ለማየት ይግቡ
ሙሉውን የፓተንት ፖርትፎሊዮ ከሕትመት ቁጥሮች፣ ቀናት እና ቤተሰቦች ጋር ያስሱ።
ይግቡ በኢሜይልዎ መለያ ይፍጠሩነፃ ነው
በመቀጠል፣ በHeelky ተጠቃሚ ስምምነት፣ በግላዊነት ፖሊሲ እና በኩኪ ፖሊሲ ይስማማሉ።
የሕግ መረጃ
| ሕጋዊ ስም | Dendreon Corporation |
|---|---|
| LEI | 549300C0XK81HDI8KK82በGLEIF ላይ ይመልከቱ ↗ |
| የተመዘገበ አድራሻ | Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US |
| ሁኔታ | ንቁ |
ምንጮች: GLEIF · የተዘመነ Oct. 16, 2026
እውቂያ & አገናኞች
ቦታ
Corporation Trust Center, 1209 Orange Street, 19801, Wilmington, US
ይህ ኩባንያዎ ነው?
አርማዎን፣ ምርቶችዎን፣ ፎቶዎችዎን እና ሥራዎችዎን ለመጨመር እና ግምገማዎችን ለመመለስ ይህን ገጽ በነፃ ይውሰዱ።
ይህን ገጽ ይውሰዱለመገናኘት፣ ለመቅጠር እና ለማደግ Heelkyን ይቀላቀሉ
ለሰዎች መልዕክት ለመላክ፣ ለሥራ ለማመልከት እና ተልዕኮዎችን ለመለጠፍ ነፃ መለያ ይፍጠሩ።
አሁን ይቀላቀሉ — ነፃ ነው